Anna Nance, APRN
Primary Care · Socorro, NMNPI 1538775382
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations.
Across 44 payments — averaging $24.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$234
- Organon$154
- Gilead$120
- Pfizer$112
- Neurocrine Biosciences, Inc.$70
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$64
- plus $322 from 10 others
What the payments were for
- Food & beverage$1,077100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 11 | $234 |
| Organon | 1 | $154 |
| Gilead | 1 | $120 |
| Pfizer | 6 | $112 |
| Neurocrine Biosciences, Inc. | 4 | $70 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $64 |
| Exact Sciences | 3 | $56 |
| Mylan Specialty L.p. | 2 | $53 |
| Novo Nordisk | 3 | $49 |
| Johnson & Johnson | 2 | $48 |
| Lilly USA, LLC | 2 | $31 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Abbott | 1 | $19 |
| GSK | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,077 in reported general payments places this provider in the 80th percentile of 58 primary care providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 46 | $65,006 |
| TrulicityDulaglutide | 33 | $52,020 |
| JardianceEmpagliflozin | 39 | $45,558 |
| EliquisApixaban | 30 | $41,316 |
| OzempicSemaglutide | 15 | $30,728 |
| FarxigaDapagliflozin Propanediol | 20 | $30,169 |
| XareltoRivaroxaban | 27 | $25,990 |
| JanuviaSitagliptin Phosphate | 11 | $16,614 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $9,603 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 59 | $6,681 |
| Arnuity ElliptaFluticasone Furoate | 11 | $6,532 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $4,159 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 135 | $3,730 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 15 | $3,425 |
| Ventolin HfaAlbuterol Sulfate | 16 | $2,983 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $31 | $117,02679 claims |
| PfizerEliquis | $112 | $41,31630 claims |
| Novo NordiskOzempic | $49 | $30,72815 claims |
| Johnson & JohnsonXarelto | $48 | $25,99027 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $16 | $16,13426 claims |
| AbbVieSynthroid, Armour Thyroid | $234 | $2,75427 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 58 primary care providers in New Mexico.
Other primary care in Socorro
- Bianca MezaAlbuquerque$59K
- Melissa PinoAlbuquerque$4K
- Jacqueline MessierAlbuquerque$3K
- Christine MayesAlbuquerque$2K
- Rachel VanwetteringAlbuquerque$2K
- Catherine JamesAlbuquerque$2K
- Christine VargaSanta Fe$2K
- Reavis BellClovis$1K
- Koryn MichaudAlbuquerque$1K
- Christine DrapeauLos Ranchos$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.